Microviable has received the 2025 Microbiome Research Reports High-Impact Paper Award, a recognition to an outstanding scientific review manuscript published in 2025 in the journal Microbiome Research Reports.

Our CTO, David Ríos Covián, PhD, lead this publication coauthor by other scientists of our team, Pilar Manrique, PhD, Ignacio Montero, PhD, Marta F. Gosende and Noelia Martínez, PhD

In this review, we summarize the influence of the gut microbiota on the development of infectious disease and cancer, which are two of the main targets of microbiome-based therapies currently being developed. We analyze the two-way interaction between the gut microbiota and traditional drugs in order to emphasize the influence of gut microbial composition on drug effectivity and treatment response. We explore the different strategies currently available for modulating this ecosystem to our benefit, ranging from 1st generation intervention strategies to more complex 2nd generation microbiome-based therapies and their regulatory framework. Lastly, we finish with a quick overview of what we believe is the future of these strategies, that is 3rd generation microbiome-based therapies developed with the use of artificial intelligence (AI) algorithms.

If you want to know more, check out the special interview the journal has organized with David after receiving the award: “In this interview, he shared insights on gut microbiota metabolism, key advances and challenges in microbiome-based therapies, and the translation of microbiome research into practical applications, highlighting the intersection of fundamental science and translational research”.

 

You can access the scientific manuscript here: https://www.oaepublish.com/articles/mrr.2023.80